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PMH49
PERFORMANCE OF THE SF-12 AND RAND-12
PHYSICAL AND MENTAL HEALTH SUMMARY
SCORES IN PEOPLE PRACTICING 
MEDITATION
Treesak C,Ye X, Sakthong P, Gross CR
University of Minnesota, Minneapolis, MN, USA
OBJECTIVES: Previous studies suggested that the per-
formance of RAND-36 summary scores was better than
that of the SF-36 in discriminating groups with different
health status. Meditation is a complementary therapy
posited to improve quality of life. Our aim is to compare
the performance of SF-12 and RAND-12 summary scores
in a sample of people practicing meditation. METHODS:
Data from a convenience sample of 141 subjects practic-
ing meditation were abstracted from a larger, cross-
sectional study. Generalized linear models were used to
compare physical and mental summary scores of the SF-
12 (PCS12 and MCS12) and RAND-12 (PHC and MHC)
adjusted for age, gender, education, and income among
known groups deﬁned by quartiles of: 1) number of co-
morbidities, 2) overall quality of life (VAS-QOL); and 3)
meditation practice time. RESULTS: Compared to the
general population, the subjects had comparable physi-
cal and mental summary scores. As anticipated, all the
summary scores (PCS12, MCS12, PHC, and MHC)
decreased with the increasing number of co-morbidities,
and increased with increasing VAS-QOL and meditation
time. All measures were signiﬁcantly different across
groups deﬁned by number of co-morbidities (p < .05)
while the MHC had the highest relative validity (F3,118
= 7.65, p < .001). Furthermore, the MHC was the only
measure to distinguish subjects grouped by VAS-QOL (p
= .01) or meditation time (p = .09). Correlation between
PHC and MHC was small and positive (r = .246, p < .01).
However, correlation between PCS12 and MCS12 was
negative (r = -.384, p < .01) which is inconsistent with
the assumption of no correlation which forms the basis
of the SF-12 algorithm. CONCLUSIONS: Our study
shows the RAND-12 summary scores are more sensitive
in detecting differences in mental health among people
practicing meditation. Moreover, the use of SF-12
summary scores may be problematic because of the coun-
terintuitive correlation between the two scores and the
RAND-12 summary scores may be a better alternative.
PMH50
COMORBID DIABETES AND SCHIZOPHRENIA:
IMPACT ON HEALTHCARE RESOURCE USE
Mackell JA,Warrington LE, Loebel A
Pﬁzer Inc, New York, NY, USA
OBJECTIVES: We compared the use of healthcare
resources in patients with schizophrenia alone, com-
orbid diabetes and schizophrenia, and diabetes alone.
METHODS: In June 2002, 850 people with schizophre-
nia, identiﬁed through the National Alliance for the Men-
tally Ill and community mental health centers, completed
self-administered questionnaires. Of these, 109 (12.8%)
reported comorbid diabetes. For comparison, a random
sample of 1000 persons with type 2 diabetes (18 to 64
years old) was generated from a similar study of 4721
people with diabetes. Data on emergency room (ER) visits
and hospitalization during the past six months were col-
lected for all respondents. Costs were calculated using
Statistical Abstracts of the United States: 2000 (ER:
$320/visit; hospitalization: $1126/day). Gender, age, and
race were controlled using multiple regression analysis.
RESULTS: Patients with schizophrenia averaged 3.3 days
more hospitalized (P = 0.004) than patients with diabetes
alone (additional cost: $3700). Patients with comorbid
schizophrenia and diabetes averaged 1.2 ER visits more
(P < 0.001) and 11.3 days more hospitalized (P < 0.001)
than patients with diabetes alone (additional costs: $396
and $12,800, respectively), and 1.0 ER visit more (P =
0.001) and 8.1 days more hospitalized (P > 0.001) than
respondents with schizophrenia alone (additional costs:
$319 and $9100, respectively). CONCLUSION: Comor-
bid schizophrenia and diabetes are associated with sig-
niﬁcantly greater healthcare resource use and costs of care
than either diabetes or schizophrenia alone.
PMH51
IMPACT OF COMORBID DIABETES ON
FUNCTIONING IN SCHIZOPHRENIA
Mackell JA,Warrington LE, Loebel A
Pﬁzer Inc, New York, NY, USA
OBJECTIVES: Use of conventional and atypical antipsy-
chotics in persons with schizophrenia has been associated
with increased risk of developing type 2 diabetes. We
studied the potential link between comorbid diabetes 
and functional status in persons with schizophrenia.
METHODS: In June 2002, 850 people with schizophre-
nia, identiﬁed through the National Alliance for the Men-
tally Ill and community mental health centers, completed
self-administered questionnaires. Of these, 109 (12.8%)
respondents had diabetes. Subjects were asked how many
hours per week they typically engaged in paid employ-
ment, volunteer work, or school/college work. Those who
participated in at least one of these activities were con-
sidered to engage in productive activity. Gender, age, and
race were controlled using multiple regression analysis for
hours per week of productive activity and logistic regres-
sion for participation in productive activity. RESULTS:
Compared with those with diabetes, respondents without
diabetes were 1.97 (P = 0.002) times as likely to partici-
pate in productive activities. Paid employment was 2.57
(P < 0.001) times more likely; volunteer work, 1.56 (P =
0.073) times more likely; and school/college work, 7.32
(P < 0.001) times more likely. Respondents without dia-
betes averaged 12.41 (P < 0.001) more hours per week of
productive activity than those with diabetes. CONCLU-
SION: Among people with schizophrenia, comorbid dia-
